717 completed, 167 recruiting, 148 active not recruiting, 111 terminated. 335 Phase 1, 312 Phase 2, 303 Phase 3, 67 Phase 4, 24 Not applicable.
Follow AbbVie: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer Telisotuzumab Adizutecan, Docetaxel, Ramucirumab - Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Not yet recruiting | AbbVie | 660 | 2027-01-06 | 2026-10-05 |
| Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations Ibrutinib Oral Tablet, Venetoclax Oral Tablet, Epcoritamab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 44 | 2026-12-31 | 2026-07-31 |
| Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Universitätsklinikum Hamburg-Eppendorf | 220 | 2026-12-01 | 2026-05-20 |
| Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy Epcoritamab, Lenalidomide - Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Refractory Large B-cell Lymphoma (LBCL) | Phase 2 | Not yet recruiting | The Lymphoma Academic Research Organisation | 55 | 2026-12-01 | 2026-09-10 |
| A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma Etentamig, Pomalidomide, Daratumumab - Relapsed or Refractory Multiple Myeloma | Phase 3 | Not yet recruiting | AbbVie | 520 | 2026-11-30 | 2026-07-27 |
| Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis Etentamig, Daratumumab, Cyclophosphamide - Amyloid Light Chain (AL) Amyloidosis | Phase 3 | Not yet recruiting | AbbVie | 370 | 2026-11-29 | 2026-08-28 |
| Study to Assess Adverse Events and How Oral ABBV-1162 Moves Through the Body of Healthy Adults ABBV-1162, Placebo - Healthy Volunteers | Phase 1 | Not yet recruiting | AbbVie | 40 | 2026-11-02 | 2026-09-22 |
| Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis Upadacitinib - UC - Ulcerative Colitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 50 | 2026-10-15 | 2026-09-24 |
| A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines TrenibotulinumtoxinE and OnabotulinumtoxinA, Placebo, OnabotulinumtoxinA - Upper Facial Lines, Glabellar Lines | Phase 2 | Recruiting | AbbVie | 300 | 2026-10-07 | 2026-10-13 |
| A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Receiving Epcoritamab Injections Diffuse Large B-Cell Lymphoma | Not yet recruiting | AbbVie | 175 | 2026-10-02 | 2026-10-07 | |
| Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations Upadacitinib, Placebo - JAK1 GOF, STAT1 GOF | Phase 1 / Phase 2 | Not yet recruiting | Lisa Satter | 30 | 2026-10-01 | 2026-09-08 |
| HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies Capivasertib, Venetoclax, Dexamethasone - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Phase 1 / Phase 2 | Not yet recruiting | Princess Maxima Center for Pediatric Oncology | 42 | 2026-10-01 | 2025-09-16 |
| Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Kerry Rogers | 155 | 2026-10-01 | 2026-08-31 |
| Risankizumab for Refractory Perianal Fistulizing Crohn's Disease Risankizumab - Crohn Disease, Perianal Fistula | Phase 4 | Not yet recruiting | Yuki Horio | 25 | 2026-10-01 | 2026-10-19 |
| Effectiveness of Upadacitinib and Biologics for the Achievement of Minimal Disease Activity in Adults With Moderate-to-Severe Atopic Dermatitis (RAMpUp) Atopic Dermatitis | Not yet recruiting | AbbVie | 900 | 2026-09-30 | 2026-08-03 | |
| A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis Upadacitinib 30mg Dose, Upadacitinib Matching Placebo - EoE, Eosinophilic Esophagitis | Phase 2 | Recruiting | University of North Carolina, Chapel Hill | 52 | 2026-09-30 | 2026-10-06 |
| A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants ABBV-1480, Pembrolizumab, Carboplatin - Non-Small Cell Lung Cancer | Phase 3 | Recruiting | AbbVie | 940 | 2026-09-22 | 2026-10-20 |
| A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy Adults ABBV-7828, Placebo for ABBV-7828 - Healthy Subjects | Phase 1 | Not yet recruiting | AbbVie | 60 | 2026-09-21 | 2026-10-05 |
| Safety and Effectiveness of NOA HYDRATION Injectable Gel for the Improvement of Skin Quality Including Attributes Such as Skin Smoothness NOA HYDRATION - Skin Quality | Phase 3 | Recruiting | AbbVie | 150 | 2026-09-16 | 2026-10-19 |
| A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors ABBV-253 - Advanced Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 | Recruiting | AbbVie | 130 | 2026-09-14 | 2026-10-16 |
Showing 20 of 1243. Sign in to see all of them.
Neoplasms (141) · Hepatitis C (87) · Hepatitis C, Chronic (80) · Leukemia, Myeloid, Acute (69) · Psoriasis (59) · Crohn Disease (57) · Arthritis, Rheumatoid (55) · Colitis, Ulcerative (47) · Leukemia, Lymphocytic, Chronic, B-Cell (43) · Carcinoma, Non-Small-Cell Lung (42) · Multiple Myeloma (42) · Recurrence (40) · Parkinson Disease (34) · Dermatitis, Atopic (33) · Arthritis, Psoriatic (29)
venetoclax (137) · risankizumab (70) · upadacitinib (69) · Adalimumab (54) · Dexamethasone (46) · Ribavirin (40) · ombitasvir (40) · dasabuvir (39) · paritaprevir (39) · Carboplatin (31) · glecaprevir and pibrentasvir (29) · Azacitidine (28) · Rituximab (28) · budigalimab (28) · Botulinum Toxins, Type A (25)
United States (724) · Spain (277) · Canada (270) · Germany (256) · Australia (228) · Japan (228) · France (222) · United Kingdom (212) · Italy (210) · Israel (188) · Poland (160) · South Korea (159) · Belgium (158) · Taiwan (144) · Puerto Rico (141)
Eric Cohen, MD (4) · Andrey Strugovschikov, MD (3) · Armen Asatryan, MD (3) · Emily Dumas, PhD (3) · Susumu Matsuki, BS (3) · Yan Luo, MD (3)
PMID 40875187, PMID 30739368, PMID 36754548, PMID 30977945, PMID 37982966, PMID 30012435, PMID 30923816, PMID 37945286, PMID 31568620, PMID 34041702, PMID 30529905, PMID 31610021, PMID 35829925, PMID 31054118, PMID 31667790, PMID 34878624, PMID 36715850, PMID 37308218, PMID 30868245, PMID 33115760, PMID 36125701, PMID 36178584, PMID 31023700, PMID 34921669, PMID 35174470, PMID 36794283, PMID 38620092, PMID 38683479, PMID 38863178, PMID 39624020, PMID 41264726, PMID 41763462, PMID 27411694, PMID 29290251, PMID 29476499, PMID 29909549, PMID 29982805, PMID 32621325, PMID 32945631, PMID 33650259, PMID 33963686, PMID 35714786, PMID 37043227, PMID 37224198, PMID 37247226, PMID 37368103, PMID 38492903, PMID 38492904, PMID 38982567, PMID 39054592
2023 (61), 2016 (43), 2015 (41), 2014 (38), 2019 (31), 2017 (26), 2025 (20), 2018 (18), 2009 (4), 2008 (2), P30CA060553 (2), 4UH3TR003908 (1), K08AR080844 (1), K23AR080043 (1), P30CA072720 (1)